Lilly, Boehringer Ingelheim collaborating on clinical trial

By Melissa Fassbender

- Last updated on GMT

Enrollment is set to begin late this year. (Image: iStock)
Enrollment is set to begin late this year. (Image: iStock)

Related tags Boehringer ingelheim Cell cycle Signal transduction

Eli Lilly and Company and Boehringer Ingelheim have announced that they are collaborating on a clinical trial in metastatic breast cancer.

The Ph1b study will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralizing antibody.

Following results from the Ph 1b trial, the collaboration may extend to Ph II trials in patients with HR+, HER2- mBC and other solid tumors.

According to Lilly, “The rationale for the collaboration is based upon the hypothesis that these two agents, in combination, could offer a more complete pathway interference and could potentially prolong cell cycle arrest. For HR+, HER2- mBC patients, this could translate to a reversal of resistance to hormone therapy​.”

Boehringer Ingelheim will be the sponsor of the study program and enrollment is set to begin late this year.

Lilly is not disclosing any additional details at this point.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us

Products

View more

Webinars